Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. - Budde LE; Olszewski AJ; Assouline S; Lossos IS; Diefenbach C; Kamdar M; Ghosh N; Modi D; Sabry W; Naik S; Mehta A; Nakhoda SK; et al. (Nature medicine, 2024)